ProfileGDS5678 / 1417065_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 88% 88% 87% 87% 89% 91% 90% 91% 88% 89% 87% 85% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.7697588
GSM967853U87-EV human glioblastoma xenograft - Control 26.92788
GSM967854U87-EV human glioblastoma xenograft - Control 36.8529488
GSM967855U87-EV human glioblastoma xenograft - Control 46.8725387
GSM967856U87-EV human glioblastoma xenograft - Control 56.8029687
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.7821289
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.2873691
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.1854190
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.410791
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.9280388
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9938389
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.7898587
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.3647885
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.9622789